TIDMMTPH

RNS Number : 5669J

Midatech Pharma PLC

27 April 2022

27 April 2022

Midatech Pharma PLC

("Midatech" or the "Company")

Issue of Equity for Midatech Employee Share Incentive Plan

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that, conditional on admission to trading on AIM, it has issued and allotted 25,000 new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares"), which are to be purchased at nominal value by the Midatech Pharma Share Incentive Plan, an employee share incentive trust.

Application has been made for the 25,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place at 8.00 a.m. on or around 3 May 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

Following Admission, the Company will have 98,493,413 Ordinary Shares in issue, none of which are held in treasury. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)29 2048 0180 
 www.midatechpharma.com 
 
 Strand Hanson Limited (Nominated and Financial Adviser) 
 James Dance / Matthew Chandler / Rob Patrick 
 Tel: +44 (0)20 7409 3494 
 
 Turner Pope Investments (TPI) Limited (Broker) 
 Andrew Thacker / James Pope (Corporate Broking) 
  Tel: +44(0)20 3657 0050 
 
   IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Alyssa Factor 
  Tel: +1 (860) 573 9637 
  Email: afactor@edisongroup.com 
           About Midatech Pharma PLC 
            Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
            MTP) is an R&D company focused on 'Making Medicines Better' 
            by improving delivery of drugs in the body. The Company combines 
            existing medications with its proprietary and innovative drug 
            delivery technologies to provide compelling oncology and rare 
            disease products that have the potential to powerfully impact 
            the lives of patients undergoing treatment for life threatening 
            diseases. 
            The Company has developed three in-house technology platforms, 
            each with its own unique mechanism to improve delivery of 
            medications to sites of disease. All of the Company's technologies 
            have successfully entered human use in the clinic, providing 
            important validation of the potential for each platform: 
             *    Q-Sphera(TM) platform: a disruptive micro-technology 
                  used for sustained release to prolong and control the 
                  release of therapeutics over an extended period of 
                  time (from weeks to months). 
 
 
             *    MidaSolve(TM) platform: an innovative nanotechnology 
                  used to dissolve insoluble drugs so that they can be 
                  administered in liquid form directly and locally into 
                  tumours. 
 
 
             *    MidaCore(TM) platform: a leading edge nanotechnology 
                  used for targeting medications to sites of disease. 
 
 
 
            By improving bio-delivery and biodistribution of approved 
            existing molecules, Midatech's unique R&D has the potential 
            to make medicines better, lower technical risks, accelerate 
            regulatory approval and route to market, and provide newly 
            patentable products. The platform nature of the technologies 
            allows the potential to develop multiple drug assets rather 
            than being reliant on a limited number of programmes. 
            Midatech's technologies are supported by 36 patent families 
            including 120 granted patents and an additional 70 patent 
            applications. 
            Midatech's headquarters and R&D facility is in Cardiff, UK. 
            For more information please visit www.midatechpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEPPURACUPPGGM

(END) Dow Jones Newswires

April 27, 2022 08:00 ET (12:00 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Midatech Pharma Charts.
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Midatech Pharma Charts.